Fifth of Wet AMD Patients Abandon Treatment

A significant proportion of patients undergoing treatment for neovascular (wet) age-related macular degeneration (AMD) are discontinuing their care without providing a reason, according to findings from a large, multicenter Canadian cohort study. The research identified that 527 out of 2,556 patients, representing approximately 20.6%, ceased their treatment regimen during long-term follow-up. This rate of attrition underscores a critical challenge in managing this chronic eye condition, which requires ongoing therapeutic intervention to preserve vision.

Wet AMD is a leading cause of irreversible blindness in individuals over the age of 50. It occurs when abnormal blood vessels grow under the macula, a central part of the retina responsible for sharp, detailed vision. These new vessels are fragile and can leak fluid or blood, causing rapid and severe vision loss. Standard treatments, such as intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents, are highly effective in halting disease progression and often improving vision. However, these treatments necessitate regular, often monthly, injections over extended periods, making adherence a crucial factor for sustained visual health.

The study, which analyzed data from a substantial patient group across multiple Canadian centers, aimed to quantify the extent of treatment discontinuation and identify potential contributing factors. While the exact reasons for the observed 20.6% dropout rate were not detailed in the initial report, common barriers to long-term treatment adherence in chronic diseases include financial costs, transportation difficulties, the burden of frequent appointments, side effects of medication, and a lack of perceived benefit or understanding of the necessity for continued therapy. For wet AMD patients, the commitment to regular clinic visits and injections can be particularly demanding.

This high rate of patients lost to follow-up has significant implications for public health and clinical practice. When patients stop treatment, their wet AMD can progress unchecked, leading to irreversible vision loss and a substantial decrease in quality of life. It also complicates the accurate assessment of treatment efficacy in real-world settings and may lead to an underestimation of the true burden of the disease. Future research and clinical strategies will likely need to focus on developing more robust patient support systems, improving patient education, and exploring methods to enhance treatment adherence to mitigate the long-term consequences of this widespread issue in wet AMD management.